Press releases
- MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 3.43 |
Average volume | -- |
---|---|
Shares outstanding | 6.66m |
Free float | 6.62m |
P/E (TTM) | 0.7133 |
Market cap | 18.66m USD |
EPS (TTM) | 3.93 USD |
Data delayed at least 15 minutes, as of Apr 17 2023 07:36 BST.
More ▼